| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
Cefpodoxime sodium (R3763 sodium; U76253A) is a broad spectrum antibacterial agent that acts by binding to penicillin binding proteins (PBPs), thus inhibiting peptidoglycan synthesis, leading to disruption of bacterial cell wall biosynthesis. Cefpodoxime is active against most Gram-positive and Gram-negative organisms. Cefpodoxime Proxetil has been widely used to treat acute otitis media, pharyngitis, sinusitis, and gonorrhea.
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Limited information suggests that low concentrations of cefpodoxime in breast milk are not expected to have any adverse effects on breastfed infants. There are reports that cephalosporins occasionally disrupt the infant's gut microbiota, leading to diarrhea or thrush, but these effects have not been adequately assessed. Cefpodoxime is safe for use by breastfeeding women. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Lactation and Breast Milk A 40-year-old non-pregnant woman developed hyperprolactinemia and bilateral galactorrhea after taking cefpodoxime 200 mg twice daily for two days. Seven days after discontinuation of the medication, the galactorrhea resolved, and serum prolactin levels significantly decreased to the normal range. One month later, prolactin levels decreased further. Since no other cause was found, the authors believe that the galactorrhea and hyperprolactinemia were most likely caused by cefpodoxime. A 22-year-old woman was taking extended-release venlafaxine 150 mg/day for 3 months. Two weeks ago, she started taking cefpodoxime 200 mg/day for 14 days. Afterward, she experienced bilateral breast engorgement and galactorrhea, lasting for 3 days. Laboratory tests and a head CT scan were normal, with only a slight elevation in alkaline phosphatase and elevated serum prolactin levels. Within two weeks, her galactorrhea began to lessen and disappeared after three weeks, during which time the venlafaxine dosage remained unchanged. Her serum prolactin levels also returned to normal. The authors believe that her symptoms and hyperprolactinemia were likely caused by cefpodoxime. For mothers who have established lactation, prolactin levels may not affect their ability to breastfeed. |
|---|---|
| References |
Drug Dev Ind Pharm. 2021 Aug;47(8):1261-1278.
|
| Additional Infomation |
Cefpodoxime is a third-generation cephalosporin antibiotic, with a methoxy group at the C-3 position of its cephalosporin core.
|
| Molecular Formula |
C15H16N5NAO6S2
|
|---|---|
| Molecular Weight |
449.43
|
| Exact Mass |
449.044
|
| CAS # |
82619-04-3
|
| Related CAS # |
80210-62-4 (free acid);82619-04-3 (sodium);87239-81-4 (Proxetil);79287-88-0 (HCl); 82623-37-8 (TFA);
|
| PubChem CID |
23669317
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.58g/cm3
|
| Index of Refraction |
1.67
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
29
|
| Complexity |
751
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C(C1=C(COC)CS[C@@H]2[C@@H](C(N12)=O)NC(=O)/C(/C1=CSC(N)=N1)=N\OC)(=O)O.[Na]
|
| InChi Key |
JNMXSNGAMPXCDR-XYNKDNFRSA-M
|
| InChi Code |
InChI=1S/C15H17N5O6S2.Na/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7;/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24);/q;+1/p-1/b19-8-;/t9-,13-;/m1./s1
|
| Chemical Name |
sodium;(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
|
| Synonyms |
R-3746 R 3746 Cefpodoxime sodium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2250 mL | 11.1252 mL | 22.2504 mL | |
| 5 mM | 0.4450 mL | 2.2250 mL | 4.4501 mL | |
| 10 mM | 0.2225 mL | 1.1125 mL | 2.2250 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
